Sirolimus vs mycophenolate mofetil in Tacrolimus based therapy after induction with Antithymocyte globulin promote regulatory T cell expansion and inhibit RORγt and T-bet expression in kidney transplantation

Saeideh Jamali1, Abdolfatah Sarafnejad1, Pedram Ahmadpoor2, Mohsen Nafar2, Mozhdeh Karimi1, Atefeh Eteghadi1, Mir Saeed Yekaninejad4, Ali Akbar Amirzargar1,5*

1Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2Chronic kidney disease research center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
5Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Accumulating evidence suggests that Regulatory T cells (Tregs) have a crucial role in immune tolerance and long-term graft survival. However, the influence of immunosuppressive drugs on the level of Tregs has not been fully understood. Therefore in this study we prospectively compare the effect of two different calcineurin inhibitor (CNI)-based immunosuppressive protocols on Tregs frequencies and Treg-related genes expression in renal transplant recipients.

Methods: The study included 24 renal transplant recipients who received induction therapy (Antithymocyte globulin) and were on triple immunosuppressive therapy; one group on Tacrolimus (TAC), mycophenolate mofetil (MMF) and prednisolone (P) and other group on TAC, Sirolimus (SRL) and P. The frequency of circulating Treg cells were analyzed by flow cytometry before and 4 months after transplantation. In addition, the mRNA expression of FOXP3, T-bet, GATA3 and RORγt were estimated by quantitative RT-PCR before and 4 months after transplantation.

Results: All recipients had significantly increased CD4+CD25+FOXP3+Treg cell levels after transplantation compared to baseline. Patients receiving MMF protocol had significantly higher CD4+CD25+FOXP3+Treg cells compared to patients on SRL. There was no significant difference between the two groups MMF and SRL in frequency of CD3+CD8+CD28- Tregs. FOXP3 mRNA levels were increased 4 months after transplantation and the expression was significantly higher in group MMF recipients. On the other hand T-bet and RORγt expression was significantly lower in group SRL in comparison to MMF group. We did not observe significant difference in GATA3 mRNA level between the two groups.

Conclusions: Our results suggest that regimen containing MMF despite increasing CD4+CD25+FOXP3+Tregs significantly, but cannot decrease RORγt and T-bet expression as well as the regimen containing SRL.

Introduction

Recent improvement in immunosuppressive medications and therapy, make kidney transplantation as a standard treatment for end-stage renal disease (ESRD) [1]. However, these drugs cannot prevent the chronic rejection of the transplantation, and also prolonged use of these drugs increase the risk of various types of malignancies and infections [2]. So avoiding long-term immunosuppression with the goal of achieving immunological tolerance can be considered as a final solution for long-term survival of allograft [3]. There is scattered evidence that allograft tolerance is often accompanied with a specialized population of regulatory T lymphocytes (Treg) [4]. Currently, most therapeutic regimens based on Calcineurin inhibitors (CNI) like Tacrolimus (TAC), significantly decrease the rate of acute rejection [5]. But long-term treatment with CNI is associated with side effects such as nephrototoxicity and vascular disease [6]. Therefore, mTOR inhibitors such as Sirolimus (SRL) and antimetabolite like Mycophenolate Mofetil (MMF) are used in combination with CNI to decrease the CNI dose and hence its related nephrotoxicity side effects [7]. The results of different studies in recent years have shown that Sirolimus decrease the rate of allograft rejection and also selectively expand Treg populations [8-11]. In addition various transplant models has revealed that MMF...
has a positive effect on the process of tolerance induction [12-14]. Considering the Regulatory T cells subsets (Tregs) and their crucial role in immune tolerance and long-term graft survival, we evaluated two subset of Treg: CD4+ CD25+ Tregs [15,16] and the CD8+ CD28- Tregs that can induce tolerance [17-19]. Since the central role of Treg in the induction of tolerance and the irreversible side effect of immunosuppressive agents on allograft survival, in this study we aimed to investigate the frequency of (CD4+ CD25+ FOXP3+) and CD8+ CD28-) Tregs and also the expression of Foxp3, T-bet, GATA-3 and RORγT genes in peripheral blood of kidney transplant recipients under immunosuppression either MMF/Tacrolimus or SRL/Tacrolimus before transplantation and 4 months after transplantation.

Materials and methods

Patients and study design

In this study we analyzed 24 blood samples from recipient of first kidney transplant (15 males and 9 females) between May 2016 and August 2017 at the transplantation unit of Labbafinejad medical center (Tehran, Iran). The local ethics committee approved all aspects of the study protocol and also written informed consent was obtained from all patients before inclusion in this study. Peripheral blood was collected just before the assumption of immunosuppressive therapy and at 16 weeks after transplantation and immunosuppressive utilization. At the time of transplant, operation patients were randomly grouped according to one of the two immunosuppressive regimen: (1) MMF group: Mycophenolate mofetil (MMF), Tacrolimus (TAC) and prednisolone (n=14), and (2) SRL group: Sirolimus (SRL), TAC and prednisolone (n=10).

All recipients received induction therapy with Anti-thymocyte globulin (ATG) (3 mg/kg) for 4 days and receive prednisolone 250 mg for 2 days and then 1 mg/kg (max 60 mg) for 3 days, the medication has been reduced to 15 mg in 14 days and the 10 mg dose is continued for up to 30 days to ultimately reach 5 mg per day.

MMF group: In this group the initial dose of TAC was 0.1 mg/kg per day orally, and target through levels were 8-10 ng/ml during the first 3 months and 5-8 ng/ml afterward. The dose of MMF (360 mg was administered in 3 divided dose for 7 days) and then will increase to 720 mg/day.

SRL group: The initial dose of TAC in this group is lower 0.08 mg/kg per day, and target through levels were 6-7 ng/ml during the first 6 months and 4-5 ng/ml afterward. The dose of Sirolimus was 2 mg for 96 hours of surgery and then 1 mg/day to reach a plasma level of 3-5 ng/ml in the first 6 months and then increase the dose to reach a plasma level of 6-8 ng/ml.

PBMC isolation: The blood specimens were collected in EDTA tubes and peripheral blood mononuclear cells (PBMC) were isolated from whole blood by density gradient centrifugation on ficoll-plaque (ino-train, germany). PBMC was frozen in a cryoprotective media containing 10% dimethyl sulfoxide (DMSO) and 90% fetal bovine serum (FBS) and stored at -196°C.

Flow cytometric analysis: For analysis of Tregs, after thawing PBMC, this cell was washed twice with phosphate-buffered saline containing 0.3% fetal bovine serum. To determine surface markers, the cells were first stained with the following fluorochrome-conjugated monoclonal antibodies (all from eBioscience, San Diego, CA): Anti-CD3-PE-Cyanine 5.5, Anti-CD8a-FITC, Anti-CD28-PE, Anti-CD4-FITC, Anti-CD25-PE. After primary incubation (30 min at 4°C) cells were washed, and for staining of intracellular Foxp3 (anti-FOXP3-PE-Cyanine5.5, eBioscience), the cell fixed and permeabilized using Foxp3/Transcription Factor Staining Buffer Set supplied by eBiosciences. As a control for correcting fluorescence compensation and confirmation of antibody specificity, the appropriate mouse immunoglobulin isotype include: IgG1 K Isotype control (FITC and PE) and IgG2a K Isotype control-PE-Cyanine (eBioscience) were used. Data were obtained on FACSCalibur flow cytometer system and analyzed by CellQuest software (BD Biosciences).

Quantitative mRNA analysis by Real-time PCR

Total RNA was extracted from PBMC (5*10⁶) using the TRI Reagent RNA Isolation Reagent (Sigma-Aldrich T9424) according to the manufacturer's instructions. RNA quantity and purity were measured by NanoDrop ND-1000 Spectrophotometer. DNA template was removed by the addition of RNase-free DNase I (CinnaClon, Iran) before reverse transcription. In brief, RNA samples were reverse transcribed to complementary DNA using High Capacity cDNA Reverse Transcription kit (Cat no. 4368814, Applied Biosystems, Foster City, CA), and stored at -70°C until use. Real-time qPCR were performed to quantify transcription expression level on a Step OnePlus real-time PCR (Applied Biosystems). The TaqMan Gene Expression Assay (primer probe) used for transcription factors T-bet (Hs00894392_m1), GATA-3 (Hs00231122_m1), RORγT (Hs01076112_m1) and FOXP3(Hs0108534_m1) were also from Applied Biosystems. Gene expression was normalized to 18s rRNA (Hs99999901_s1, Applied Biosystems) as the endogenous control. In this study, pretransplant samples were taken as control sample. Transcript levels calculated using the relative quantification method 2-ΔΔct.

Statistical analysis

Data were analyzed using SPSS 16.0 software. The comparison of value before transplantation and four months after transplantation were performed using Paired t-test and between groups was made by unpaired t-test. Values are presented as the Mean (± SD) and P value less than 0.05 was recognized as significant.

Results

Basic characteristics of recipients

Demographic data and baseline characteristics are presented in Table1, whereas Table 2 shows patients’ clinical and biochemical data. There was no significant difference in age and gender between groups. All patients were first kidney transplants. 12 patients (50%) were living related donor recipients and 12 (50%) were cadaveric donor transplants. Improvement of renal function was observed as early as 4 months after transplantation in both groups. Relative to baseline value, serum creatinine decreased with a mean of 1.71 ± 0.89 (SD) in MMF group and 1.25 ± 0.42(SD) in SRL group at 4 months after transplantation. The glomerular filtration rate was measured and show a significant increase at 4 months after transplantation. There was no significant difference in GFR rate between two groups (Table 2). BUN levels also significantly decreased in both groups after transplantation and we didn’t see significant difference between two groups.

Frequencies of total CD4+ T cells in recipients

As shown in Figure1, the frequencies of CD4+ T cells in MMF group had decreased significantly 4 months after transplantation (29.10% ± 11.70%) compared with before transplantation (39.92% ± 10.49%,
We next examined CD4+CD25+FOXP3+ T Subsets that represent FOXP3 as a specific transcription factor in regulatory T cell. The frequencies of CD4+ T cells were significantly decreased 4 months after transplantation (26.61% ± 10.11) compared with before transplantation (38.46% ± 12.57, P=0.04) (Figure 1B). However, there was no significant difference in the frequencies of CD4+ T cells between MMF and SRL group (P=0.05) (Figure 1C).

Frequencies of CD4+CD8+CD28-Treg in recipients

We next examined CD4+CD8+ T subsets that represent FOXP3 as a specific transcription factor in regulatory T cell. The frequencies of CD4+CD25+FOXP3+ Tregs was (3.16 ± 1.25) before transplantation, compared with before transplantation (3.01 ± 0.75, P=0.04) (Figure 2B). However, patients receiving MMF presented higher level of CD4+CD25+FOXP3+ Tregs (4.14 ± 0.93) compared with patients on SRL (3.36 ± 0.81, P=0.04) (Figure 2C).

Figure 1. Frequencies of CD4+ T cells in 24 renal transplant recipients taking Mycophenolate mofetil (MMF) or sirolimus (SRL) at 4 months (4m) after transplantation compared to before transplantation (PreKT). The frequencies of CD4+ T cells was measured by flowcytometry. A: representative FACS picture from recipients in MMF group before and after transplantation. B: representative FACS picture from recipients in SRL group before and after transplantation. C: collective analysis of result from groups of different drugs. Bar shows median. *P<0.05 for 4m vs. PreKT.


Figure 2. Frequencies of CD4+CD25+FOXP3+ Treg cells in 24 renal transplant recipients taking Mycophenolate mofetil (MMF) or sirolimus(SRL) at 4 months(4m) after transplantation compared to before transplantation(PreKT). The frequencies of CD4+CD25+FOXP3+ Treg cells was measured by flowcytometry. A: representative FACS picture from recipients in MMF group before and after transplantation. B: representative FACS picture from recipients in SRL group before and after transplantation. C: collective analysis of result from groups of different drugs. Bar shows median. *P<0.05 for 4m vs. PreKT. *P<0.05 for MMF group vs. SRL group.
Sirolimus vs mycophenolate mofetil in Tacrolimus based therapy after induction with Antithymocyte globulin promote regulatory T cell expansion and inhibit RORγt and T-bet expression in kidney transplantation

**Figure 3.** Frequencies of CD3+CD8+CD28- Treg cells in 24 renal transplant recipients taking Mycophenolate mofetil (MMF) or Sirolimus (SRL) at 4 months (4m) after transplantation compared to before transplantation (PreKT). The frequencies of CD3+CD8+CD28- Treg cells was measured by flow cytometry. A: representative FACS picture from recipients in MMF group before and after transplantation. B: representative FACS picture from recipients in SRL group before and after transplantation. C: collective analysis of result from groups of different drugs. Bar shows median.
four months after transplantation compared to before transplantation. mTOR inhibitors such as Sirolimus and Everolimus are the new immunosuppressive drugs that unlike the tacrolimus, does not interfere with the expansion of Treg cells. Z.Q.chu, et al. in a study performed on kidney transplantation recipients showed that CNIs significantly decreases the percentage of Treg cells in Comparison to healthy subjects, while sirolimus does not change the percentage of Tregs [24]. D. Sansgundo et al. also reported that conversion the therapeutic protocol from Tacrolimus to sirolimus increases the absolute number of Treg cells [25]. However, the simultaneous use of Tacrolimus and sirolimus can suppress more effectively proliferation of alloreactive T helper cells (Th) Th1 and Th17, while maintains the population of Treg cells [26]. In line with our study combination of sirolimus with low dose of Tacrolimus increases the Tregs cells. MMF is commonly used in combination with Calcineurin inhibitors in transplantation, and significantly reduces acute rejection. There is little information about the relationship between MMF and Treg. It has been shown that MMF with vitamin D3 can induce Treg cells in the mouse model [13]. In the liver transplantation, Demirkiran et al. showed that conversion from Calcineurin inhibitors to MMF, causes an increase in the CD4+ CD25+ FOXP3+Tregs [12] while Lim et al. reported that expansion of CD4+ CD25+ Treg cells isn’t so different in presence or absence of MMF [27]. Our results showed that frequency of CD4+ CD25+ FOXP3+ regulatory T cells in MMF recipients, is significantly higher than the other group. In confirmation of our findings, Zhen Wang et al. reported that low-dose Tacrolimus plus MMF, expands CD4+ CD25+ FOXP3+ regulatory cells [28]. Also, in another study on kidney transplantation recipients, the data showed that combination of Tacrolimus and MMF, increases frequencies of CD4+ CD25+ FOXP3+ T cells in Comparison with combination of Tacrolimus and Everolimus [29]. CD3+ CD8+ CD28- cells are another subsets of regulatory cells that have recently become their role are more prominent in various transplant organs. These cells have the ability to suppress alloimmune and autoimmune reactions in many animal models, and the increase can be as a predictor biomarker of better condition of the transplanted organ. It has been observed that in heart transplant recipients, the frequency of CD8+CD28- cells is higher in comparison with normal people [17]. Y.-X. Lin et al. study on liver transplantation patients, showed that combination of Tacrolimus and MMF, increased the numbers of CD3+CD8+CD28- cells [30], while Korecka-polac et al. showed that Cyclosporine A and Rapamycin causes the suppression of CD8+CD28- cells [31]. Generally the number of CD3+CD8+CD28- cells increases in the liver transplantation and the high percentage is associated with a better graft Prognosis. However the percentage of these cells in kidney transplantation is controversial in different studies it may be related to different time point of sampling in each study as it seems to increase over time after transplantation. In the present study CD3+CD8+CD28- cells were increased after transplantation, nevertheless, we did not find a relationship between frequency of CD3+ CD8+ CD28- regulatory cells and the two different used immunosuppressive protocols. The balance between the effector T cells function and the regulatory cells is a complex mechanism that clarify the allograft outcome and survival. Tolerance or rejection are the two arms of this situation, and multiple different effective mechanisms pathways have role in these two processes. New studies are more concentrated to the plasticity of Th17 cells and the balance between the Th17 and Treg cells. It is very important to know that the Th17 and Treg cells develop from the same precursor and their development depending on the cytokine environment [32]. The imbalance of Th17/Treg in peripheral blood, is a strong predictor of CNI effects in the poor function of transplanted kidney [33]. Specific transcription factors are associated with functional evolution of various T cells such as: T-beta (Th1), GATA3 (Th2), ROYR (Th17) and foxp3 (Treg) [34]. In our study, the expression of FOXP3 and ROYR had increased in MMF group while FOXP3 has a regulatory function, ROYR were found to be elevated in inflammatory condition. In the SRL group, the expression of FOXP3 has been increased, but the expression of ROYR has decreased. It is suggested that the MMF protocol has failed to establish a balance between inflammatory and regulatory responses, while in the SRL group a safety balance is observed toward regulatory status. Heather Kopf et al. reported that sirolimus not only increases FOXP3 expression but also prevents the differentiation of the naïve T cells into Th17, and consequently, creates a more stable phenotype of CD4+ Treg cells [35]. Data from different studies have shown that Th1 and Th17 cells have a profound role in induction of inflammatory transplantation process, but the role of Th2 cells are not yet fully understood [36]. The ratio of Th1 to Th2 is very important in the prediction of allograft status. In the present study, both the therapeutic protocols suppress expression of T-beta and GATA3 genes four months after transplantation compared to before transplantation, but the SRL group prevents more effectively T-beta expression and this is in favor of the allograft survival. Yi Li et al. study showed that conversion from CNI to the sirolimus reduces frequency of Th1 and Th17 [37].

In conclusion, our data demonstrated that although in the MMF group, the frequency of CD4+ CD25+ FOXP3+ Tregs increased significantly, but on the other hand the expression of ROYR has not been well inhibited, while the SRL group increase the Treg and has meaningfully decreased the expression of ROYR. It is suggested that considering the balance between alloreactivity and tolerance, using a therapeutic regimen containing SRL has a better performance in balancing and improvement of renal function.

Acknowledgments

This project (MSc thesis) is financially supported by Tehran University of Medical Sciences, Tehran, Iran. Grant number: 30721.

References


Copyright: ©2018 Jamali S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.